RIGHTWARE
4.1.2022 08:02:14 CET | Business Wire | Press release
Rightware today released Kanzi One, concluding a highly successful and oversubscribed beta program announced in September. The first automotive HMI toolchain to be fully compatible with Android™, Kanzi One delivers industry-leading 3D graphics and a new UI workflow, empowering automakers to create compelling new user experiences with visual excellence and maximum productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005425/en/
“As announced at IAA in Munich, Kanzi One is a game-changer for creativity and productivity by automakers,” said Rightware CEO Freddie Geier. “We are grateful for the positive feedback from customers and partners since our product launch, and we eagerly await the new Signature UIs they create with Kanzi One.”
Rightware’s goal with Kanzi One is to inspire OEMs and Tier 1 suppliers with impressive rendering capabilities and a powerful 3D graphics engine, the deepest Android integration for next generation infotainment systems, and a straightforward workflow that unleashes HMI possibilities.
Kanzi One lets manufacturers deliver future-looking user experiences for advanced HMIs in less than half the time with teams half the size and with significantly less coding compared with traditional methods.
All-in-One Solution
In addition to the core Kanzi framework consisting of Kanzi Studio and Kanzi Engine, Kanzi One delivers further value to automakers by including a growing list of feature packs.
Initially, five feature packs are included: Kanzi Connect makes it easy to share data, content, and services across screens and devices; Kanzi Maps enhances navigation with creative visualization; Kanzi Particles enables astounding visual effects and animations; Kanzi Autostereoscopy enables realistic depth effects; and the new Kanzi VR makes it easy to validate designs in an early phase by placing live UIs inside a virtual car interior and interacting with the screens with or without a virtual reality headset.
“We are certain that Kanzi One will transform the in-car user interfaces of today into tomorrow’s Signature UIs—highly appealing, easy-to-use, and true to their brand,” said Geier. “We invite all friends and observers of innovation in the automotive industry to explore the possibilities of Kanzi One, and count on us to drive HMI development to the next level.”
Due to the rapidly rising health risks associated with covid, Rightware made the decision not to attend CES 2022. Instead, the company will kick off a customer road show to present Kanzi One as conditions permit. To request a virtual or in-person meeting and to read descriptions of the latest Kanzi One demonstrations, please visit www.rightware.com/kanzi-one-at-ces-2022 or contact sales@rightware.com .
About Rightware
Rightware is the company behind the Kanzi family of tools and services for design and development of advanced digital user interfaces. Our mission is to help automakers increase brand value with highly customized signature user interfaces. As a ThunderSoft company, our combined skills and assets allow us to deliver fully integrated HMI solutions, engineering support, and design services. Rightware is headquartered in Finland and has a presence in China, Germany, Italy, Japan, South Korea, UK, and USA. Kanzi is the market-leading automotive UI tool trusted by over 50 automotive brands across the globe. www.rightware.com
Android is a trademark of Google LLC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005425/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom